Source: http://www.google.com/patents/US8163723?dq=6,123,819
Timestamp: 2018-01-23 09:04:53
Document Index: 209956613

Matched Legal Cases: ['Application No. 2', 'Application No. 2', 'Application No. 10', 'Application No. 2005', 'art 2', 'Application No. 762', 'art 2', 'art 2']

Patent US8163723 - Combination of azelastine and steroids - Google Patents
A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or...http://www.google.com/patents/US8163723?utm_source=gb-gplus-sharePatent US8163723 - Combination of azelastine and steroids
Publication number US8163723 B2
Application number US 12/879,515
Also published as CA2489427A1, CA2489427C, CA2779630A1, CA2779630C, CA2779633A1, CA2779633C, CN1674910A, DE60327203D1, EP1519731A1, EP1519731B1, EP2072051A1, EP2072051B1, EP2075000A1, EP2075000B1, US8168620, US8304405, US8318709, US8933060, US8937057, US9259428, US20060025391, US20090291143, US20090318397, US20100331289, US20130029951, US20130029952, US20150072010, US20150190405, US20150224116, US20170035780, WO2003105856A1
Publication number 12879515, 879515, US 8163723 B2, US 8163723B2, US-B2-8163723, US8163723 B2, US8163723B2
Inventors Amar Lulla, Geena Malhotra
Patent Citations (128), Non-Patent Citations (238), Referenced by (6), Classifications (25), Legal Events (3)
US 8163723 B2
Sr. No Ingredients % w/v
Azelastine 140 mcg
US2837464 Jan 11, 1955 Jun 3, 1958 Schering Corp Process for production of dienes by corynebacteria
US3506694 Nov 27, 1967 Apr 14, 1970 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
US3557162 Jan 23, 1969 Jan 19, 1971 Koninklijke Gist Spiritus Process for the preparation of 17alpha-monoesters of 11beta,17alpha,21-trihydroxysteroids
US3891631 Aug 10, 1973 Jun 24, 1975 Glaxo Lab Ltd Process for preparing 17{60 -monoesters of 17{60 , 21-dihydroxy-20-oxo steroids
US4113680 Mar 29, 1976 Sep 12, 1978 Taisho Pharmaceutical Co., Ltd. Method for preparing 17 α-ester-21-halo pregnanes
US5232919 Oct 15, 1990 Aug 3, 1993 Asta Pharma Aktiengesellschaft Azelastine embonate and compositions which contain it
US5608093 Aug 25, 1994 Mar 4, 1997 Hoechst Aktiengesellschaft Corticosteroid 17-alkyl carbonate 21-[0]-carboxylic and carbonic esters, and pharmaceuticals containing these compounds
US6330938 Jun 15, 1999 Dec 18, 2001 Automobile, Peugeot Method and device for controlling an electric actuator activating a functional system
US6391340 Nov 3, 1999 May 21, 2002 Astrazeneca Ab Dry powder pharmaceutical formulation
US20040053904 Dec 21, 2001 Mar 18, 2004 Teruo Komoto Preventive/ermedies for inflammatory airway diseases
US20040136918 Mar 4, 2002 Jul 15, 2004 Garrett Ronique Nichele Pharmaceutical formulations
US20040242638 Nov 18, 2002 Dec 2, 2004 Yanni John M Use of an h1 antagonist and a safe steroid to treat rhinitis
US20050163724 Jun 13, 2003 Jul 28, 2005 Ssp Co., Ltd. Powdery respiratory tonic composition
US20050192261 Sep 14, 2004 Sep 1, 2005 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
US20060025391 Jun 13, 2003 Feb 2, 2006 Amar Lulla Combination of azelastine and steroids
US20060110331 Nov 22, 2005 May 25, 2006 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060228306 Mar 27, 2006 Oct 12, 2006 Fairfield Clinical Trials Llc Combination antihistamine and steroid medication
US20070020330 Jul 14, 2006 Jan 25, 2007 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20090286762 Jul 26, 2007 Nov 19, 2009 Glaxo Group Limited Pharmaceutical Formulations Comprising Azelastine and a Corticosteroid for the Treatment of Inflammatory or Allergic Conditions
US20090291143 Jul 23, 2009 Nov 26, 2009 Cipla Limited Combination of Azelastine and Steroids
US20090318397 Jul 23, 2009 Dec 24, 2009 Cipla Limited Combination of Azelastine and Steroids
US20100152147 Sep 29, 2009 Jun 17, 2010 Meda Pharmaceuticals Inc. Compositions Comprising Azelastine and Methods of Use Thereof
AU2003244799B2 Title not available
BE889563A Title not available
DE3836579A1 Oct 27, 1988 May 24, 1989 Asta Pharma Ag Azelastine-containing pharmaceutical compositions for use in the nose and/or on the eye
DE10152369A1 Oct 24, 2001 May 8, 2002 Boehringer Ingelheim Pharma Stable, propellant-free inhalable liquid medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium salt and antiallergic agent, antihistamine, steroid or leukotriene antagonist
DE19947234A1 Sep 30, 1999 Apr 5, 2001 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
EP0004773B1 Apr 3, 1979 Apr 29, 1981 Syntex (U.S.A.) Inc. 17-beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes, their pharmaceutical use and processes for their preparation
EP0057401B1 Jan 25, 1982 Aug 1, 1984 Schering Corporation Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
EP0393658B1 Apr 19, 1990 Mar 22, 1995 Ss Pharmaceutical Co., Ltd. Novel steroid derivatives
EP0416951B1 Sep 7, 1990 Jan 12, 1994 Glaxo Group Limited Medicaments comprising salmeterol and fluticason
EP1519731B1 Jun 13, 2003 Apr 15, 2009 Cipla Ltd. Combination of azelastine and fluticasone
EP2072051A1 Jun 13, 2003 Jun 24, 2009 Cipla Ltd. Combination of azelastine and mometasone
GB1191965A Title not available
GB2079755B Title not available
GB2389530A Title not available
IL109656D0 Title not available
WO1998048839A1 Apr 2, 1998 Nov 5, 1998 Warner-Lambert Company Topical nasal antiinflammatory compositions
WO2004013156A1 Jul 28, 2003 Feb 12, 2004 Novartis Ag Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (a) phenanthrenyl ester
WO2004019955A1 Aug 29, 2003 Mar 11, 2004 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
WO2008012338A2 Jul 26, 2007 Jan 31, 2008 Glaxo Group Limited Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1 "Azelastine," STN Registry No. 58581-89-8, STN Registry File, Retrieved Nov. 23, 2010, p. 1.
2 "Fluticasone Furoate," STN Registry No. 397864-44-7, STN Registry File, Retrieved Nov. 23, 2010, p. 1.
3 ABPI Compendium of Data Sheets and Summaries of Product Characteristics, 1999-2000, Cover Page, p. 43, and Index p. 1882, Datapharm Publications Limited, London, Great Britain.
4 ABPI Data Sheet Compendium, 1995-96, cover page plus pp. 38-39, Datapharm Publications Limited, London, Great Britain.
5 Aigbirhio, Franklin I., et al., "Automated radiosynthesis of no-carrier-added [S-fluoromethyl-18F]Fluticasone propionate as a radiotracer for lung deposition studies with PET," Journal of Labelled Compounds and Radiopharmaceuticals, vol. 39, No. 7, 1997, pp. 569-584.
6 Akerlund, Anders, et al., "Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication," J. Allergy Clin. Immunol., Mar. 2005, vol. 115, No. 3, pp. S460-S482.
7 Applicant Response to foreign communication EP Patent 1519731, Aug. 11, 2011, 252 pages.
8 Applicants' response dated Feb. 24, (2010) 2011 (8 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
9 Applicants' response dated Jun. 22, 2011 (9 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
10 Applicants' response dated Oct. 6, 2010 (8 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
11 Applicants' response dated Sep. 6, 2011 (8 pages) in U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
12 Applicants response to foreign communication—CA 2489427, Dec. 20, 2010, 10 pages.
13 Applicants response to foreign communication—EP 03738280.1 (EP Patent 1519731) , Sep. 6, 2010, 15 pages.
14 Applicants response to foreign communication—EP 03738280.1, Jan. 18, 2008, 14 pages.
15 Applicants response to foreign communication—EP 03738280.1, May 22, 2006, 36 pages.
16 Applicants response to foreign communication—KR10-2004-7020819, Dec. 27, 2010, 18 pages.
17 Astelin (azelastine hydrochloride) Nasal Spray, MedPointe Pharmaceuticals, 2006, U.S. Physicians Desk Reference, pp. 1876-1877.
18 Astepro (azelastine HCI) Nasal Spray 0.15%, Meda Pharmaceuticals Inc., 2009, Press Release, pp. 1-4.
19 Aurora, Jack, "Nasal Delivery; Development of Nasal Delivery Systems: A Review," Drug Delivery Technology, vol. 2, No. 7, Oct. 2002, 8 pages, http://www.drugdelivelytech.com/ME2/Segments/Publications: Article&id=9EB19EB2F29F462089CE081473F5F3CA.
20 Austin, et al., "Mometasone furoate is a less specific glucocorticoid than fluticasone propionate," Eur. Respir. J., 2002, vol. 20, pp. 1386-1392.
21 Avicel® RC/CL, Microcrystalline Cellulose and Carboxymethylcellulose Sodium, NF Dispersible Cellulose, BP, Specifications and Analytical Methods, RC-16 Updated Oct. 1995 (Feb. 1999), 6 pages, FMC BioPolymer.
22 Baena-Cagnani, Carlos E., "Safety and Tolerability of Treatments for Allergic Rhinitis in Children," Drug Safety 2004, vol. 27, No. 12, pp. 883-898, ADIS Data Information BV.
23 Banov, et al., "Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis," Annals of Allergy, 1994, vol. 73, pp. 240-246.
24 Barnes, M. L., et al., "Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis," Clinical and Experimental Allergy, Jan. 27, 2006, vol. 36, pp. 676-684, Blackwell Publishing Ltd.
25 Barnes, Peter J., "Chronic obstructive pulmonary disease: new opportunities for drug development," Trends in Pharmacological Sciences, vol. 19, No. 10, 1998, pp. 415-423.
26 Barnes, Peter J., "Efficacy of inhaled corticosteroids in asthma," The Journal of Allergy and Clinical Immunology, vol. 102, No. 4, 1998, pp. 531-538, 1998.
27 Barnes, Peter J., "Novel approaches and targets for treatment of chronic obstructive pulmonary disease," American Journal of Respiratory and Critical Care Medicine, vol. 160, 1999, pp. S72-S79.
28 Baumgarten, C., et al., "Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250mug) combination product (SAS 40023)," European Journal of Medical Research, 2002, vol. 7, pp. 1-7.
29 Baumgarten, C., et al., "Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250μg) combination product (SAS 40023)," European Journal of Medical Research, 2002, vol. 7, pp. 1-7.
30 Berge, Stephen M., et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, vol. 66, No. 1, Jan. 1977, pp. 1-19.
31 Berstein, et al., "Treatment with intranasal fluticasone propionate significantly improves ocular symptons in patients with seasonal allergic rhinitis," Clin. Exp. Allergy, 2004, vol. 34, pp. 952-957.
32 Biggadike, Keith, Letter to the Editor, "Fluticasone furoate/fluticasone propionate-different drugs with different properties," The Clinical Respiratory Journal, 2011, pp. 183-184.
33 Biggadike, Keith, Letter to the Editor, "Fluticasone furoate/fluticasone propionate—different drugs with different properties," The Clinical Respiratory Journal, 2011, pp. 183-184.
34 Block, John H., et al., "Inorganic Medicinal and Pharmaceutical Chemistry," 1986, cover, publication, and preface pages plus p. 100, Indian Edition, Varghese Publishing House, Bombay, India.
35 Bowler, Simon, "Long acting beta agonists," Australian Family Physician, vol. 27, No. 12, 1998, pp. 1115, 1117-1118 plus cover.
36 Brooks, et al., "Spectrum of seasonal allergic rhinitis symptom relief with topical corticoid and oral antihistamine given singly or in combination," American Journal of Rhinology, 1996, vol. 10, No. 3, pp. 193-199.
37 Bryson, et al., "Intranasal fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis," Drugs, 1992, vol. 43, No. 5, pp. 760-775.
38 Busse, William W., et al., "Corticosteroid-sparing effect of azelastine in the management of bronchial asthma," American Journal of Respiratory and Critical Care Medicine, 1996, vol. 153, No. 1, pp. 122-127, American Lung Association, New York, NY, XP-000604179.
39 Busse, William, et al., "Steroid-sparing effects of fluticasone propionate 100mug and salmeterol 50 mug administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 mug administered twice daily," J. Allergy Clin. Immunol., vol. 111, No. 1, Jan. 2003, pp. 57-65.
40 Busse, William, et al., "Steroid-sparing effects of fluticasone propionate 100μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily," J. Allergy Clin. Immunol., vol. 111, No. 1, Jan. 2003, pp. 57-65.
41 CAS Registry No. 102113-40-6, 2004.
42 CAS Registry No. 90566-53-3, "Fluticasone," Nov. 16, 1984.
43 Chapman, et al., "Anti-inflammatory activity of inhaled mometasone furoate in allergic mice," Arzneimettelforschung ("Drug Research"), 1998, vol. 48, No. 4, pp. 384-391.
44 CIPLA Annual Report Extract; 2010; (report shows that they launched an FF+azelastine product in 2010).
45 Cipla Sixty-Ninth Annual Report 2004-2005, cover pages, information page, plus pp. 3, 5, and 44.
46 CIPLA's response to Statement of Opposition for EP1519731, 2011.
47 Comparative data of azelastine with steroids, 2011.
48 Daley-Yates, et al., "Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations," Br. J. Clin. Pharmocol., 2001, vol. 51, pp. 103-105.
49 Declaration of Geena Malhotra for EP1519731 dated Aug. 11, 2011.
50 Declaration of Joachim Maus for EP1519731 dated Aug. 10, 2011.
51 Derby, et al., "Risk of cataract among users of intranasal corticosteroids," J. Allergy Clin. Immunol., 2000, vol. 105, No. 5, pp. 912-916.
52 Dewester, et al., "The efficacy of intranasal fluticasone propionate in relief of ocular symptoms associated with seasonal rhinitis," Allergy and Asthma Proc., 2003, vol. 24, No. 5, pp. 331-337.
53 Di Lorenzo, G., et al., "Randomized Placebo-controlled Trial Comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis," Clin. Exp. Allergy, 2004, vol. 34, pp. 259-267., Blackwell Publishing Ltd.
54 Dictionary of Organic Compounds, 6th Ed., vol. 1, p. 3234, definition of "fluticasone," Chapman & Hall, 1996.
55 Dolovich, et al., "Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis," Annals of Allergy, 1994, vol. 73, No. 2, pp. 147-153.
56 Drouin, Michel A., et al., "Adding Loratadine to Topical Nasal Steroid Therapy Improves Moderately Severe Seasonal Allergic Rhinoconjunctivitis," Advances in Therapy, vol. 12, No. 6, Nov./Dec. 1995, pp. 340-349, Health Communications Inc.
57 Duonase Data Sheet, "The complete rhinitis control," 6 pages, Cipla Limited, Mumbai, India, 2004.
58 Duonase Data Sheet, "The Complete Rhinitis Control," 6 pages, Cipla Limited, Mumbai, India.
59 Dykewicz, Mark S., et al., "Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology," Annals of Allergy, Asthma & Immunology, Nov. (Part II) 1998, vol. 81, pp. 478-518.
60 File history of Australian Patent Application No. AU2003244799, 38 pages.
61 File history of Brazilian Patent Application No. PI 0312128-3, 27 pages, Apr. 2011.
62 File history of Brazilian Patent Application No. PI 0312128-3, 27 pages.
63 File history of Canadian Patent Application No. 2,489,427, 19 pages, Dec. 2010.
64 File history of Canadian Patent Application No. 2,489,427, 19 pages.
65 File history of Korean Patent Application No. 10-2004-7020819, 89 pages.
66 File history of Mexican Patent Application No. PA/a/2004/01266 (now Patent No. 265349), 86 pages.
67 File history of Polish Patent Application No. P-373001, 95 pages, May 2011.
68 File history of Polish Patent Application No. P-373001, 95 pages.
69 File history of Russian Patent Application No. RU 2361593 C2, 65 pages, Apr. 2009.
70 File history of Russian Patent Application No. RU 2361593 C2, 65 pages.
71 File history of South African Patent Application No. 2005/0331 (now Patent No. 2005/0331), 18 pages.
72 Foreign communication from a related counterpart application—AU2003244799, Examination Report, Nov. 20, 2007, 2 pages.
73 Foreign communication from a related counterpart application—CA2,489,427, Examination Report, Jun. 18, 2010, 3 pages.
74 Foreign communication from a related counterpart application—CA2,489,427, Examination Report, Mar. 24, 2011, 2 pages.
75 Foreign communication from a related counterpart application—EP Application 03738280.1, Examination Report, Jul. 18, 2007, 5 pages.
76 Foreign communication from a related counterpart application—EP Application 03738280.1, Examination Report, Nov. 10, 2005, 4 pages.
77 Foreign communication from a related counterpart application—EP Application 03738280.1, Notice of Intent to Grant, Oct. 23, 2008, 6 pages.
78 Foreign communication from a related counterpart application—Examination Report, EP Application 037382801, Jul. 18, 2007, 5 pages.
79 Foreign communication from a related counterpart application—Examination Report, EP Application 037382801, Nov. 10, 2005, 4 pages.
80 Foreign communication from a related counterpart application—Examination Report, RU 2005100781, Apr. 23, 2007, 6 pages.
81 Foreign communication from a related counterpart application—Examination Report, RU 2005100781, May 23, 2008, 3 pages.
82 Foreign communication from a related counterpart application—KR 10-2004-7020819, Examination Report, Aug. 26, 2010, 8 pages.
83 Foreign communication from a related counterpart application—Notice of Opposition, EP Application 03738280.1, Feb. 22, 2010, 22 pages.
84 Foreign communication from a related counterpart application—Summons to Attend Oral Proceedings, EP Application 03738280.1, Feb. 8, 2011, 1 page.
85 Foreign communication from a related counterpart application—Translation of Office Action, Israel Patent Application 165771, Jul. 11, 2011, 3 pages.
86 Foreign communication from the priority application—International Preliminary Examination Report, PCT/GB03/02557, Aug. 26, 2004, 6 pages.
87 Foreign communication from the priority application—International Search Report, PCT/GB03/02557, Sep. 17, 2003, 3 pages.
88 Foreign communication from the priority application—Search Report, GB 0213739.6, Nov. 22, 2002, 4 pages.
89 Fowler, Stephen J., et al., "Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone," J. Allergy Clin. Immunol., vol. 109, No. 6, Jun. 2002, pp. 929-935.
90 Galant, Stanley P., et al., "Clinical Prescribing of Allergic Rhinitis Medication in the Preschool and Young School-Age Child, What are the Options?," BioDrugs2001, vol. 15, No. 7, pp. 453-463, ADIS International Ltd.
91 Garner, R. C., et al., "A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts," Journal of Pharmaceutical and Biomedical Analysis, vol. 24, 2000, pp. 197-209.
92 Gawchik, et al., "Comparison of intranasal triamcinolone acetonide with oral loratadine in the treatment of seasonal ragweed-induced allergic rhinitis," Am. J. Man. Care, 1997, vol. 3, No. 7, pp. 1052-1058.
93 Gennaro, Alfonso R., ed., et al., Remington: The Science and Practice of Pharmacy, 2000, 20th edition, vol. 1, pp. 785, 830, 831 plus cover page and publication page, Lippincott Williams & Wilkins.
94 Gilbert, Peter, et al., "Preservation of Pharmaceutical Products," Encyclopedia of Pharmaceutical Technology, 2002, 2nd edition, vol. 3, p. 2278 plus cover page and publication page, Marcel Dekker, Inc.
95 Hampel, Frank C., et al., Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device, Annals of Allergy, Asthma & Immunology, Aug. 2010, vol. 105, pp. 168-173.
96 Harding, "The human pharmacology of fluticasone propionate," Respiratory Medicine, 1990, vol. 84, Suppl. A, pp. 25-29.
97 Herrero, Vanrell, R., "Preservatives in Ophthalmic Formulations: An Overview," Arch. Soc. Esp. Oftalmol, 2007, vol. 82., pp. 531-532.
98 Hodges, N. A., et al., "Preservative Efficacy Tests in Formulated Nasal Products: Reproducibility and Factors Affecting Preservative Activity," J. Pharm. Pharmacol., 1996, vol. 48, pp. 1237-1242.
99 Hodges, Norman, et al., "Antimicrobial Preservative Efficacy Testing," Handbook of Microbiological Quality Control, Pharmaceuticals and Medical Devices, 2000, p. 168 Plus cover page and publication page, Taylor & Francis Publisher, USA and Canada.
100 Holgate, Stephen T., Difficult Asthma, 1999, cover page and publishing information.
101 Howarth, P. H., "A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis," Allergy 2000, vol. 62, pp. 6-11, Munksgaard 2000.
102 Howland, "Fluticasone propionate: topical or systemic effects?" Clinical and Experimental Allergy, 1996, vol. 26, Suppl. 3, pp. 18-22.
103 Isogai, et al., "Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue," J. Steroid Biochem. Mol. Biol., 1993, vol. 44, pp. 141-145.
104 Johansson, Gunnar, et al., "Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma," Clin. Drug Invest., vol. 21, No. 9, 2001, pp. 633-642, 11 pages.
105 Johnson, Malcom, "Development of fluticasone propionate and comparison with other inhaled corticosteroids," J. Allergy Clin. Immunol., Apr. 1998, vol. 101, No. 4, Part 2, pp. S434-S439.
106 Juniper, E F., et al., "Comparison of beclomethasone dipropionate aqueous nasal spray, astemizone, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis," Journal of Allergy and Clinical Immunology, Mar. 1989, vol. 83, No. 3, Cover page, Publications page, pp. 627-633, American Academy of Allergy and Immunology, C.V. Mosby Co.
107 Juniper, Elizabeth F., et al., "Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma," Am. J. Respir. Med., vol. 1, No. 6, 2002, pp. 435-440.
108 Kenley, Richard A., et al., "An automated, column-switching HPLC method for analyzing active and excipient materials in both cream and ointment formulations," Drug Development and Industrial Pharmacy, vol. 11 (9 & 10), 1985, pp. 1781-1796.
109 Kertesz, Denis J., et al., "Thiol esters from steroid 17beta-carboxylic acids: carboxylate activation and internal participation by 17 alpha-acylates," J. Org. Chem., vol. 51, 1986, 14 pages.
110 Kertesz, Denis J., et al., "Thiol esters from steroid 17β-carboxylic acids: carboxylate activation and internal participation by 17 α-acylates," J. Org. Chem., vol. 51, 1986, 14 pages.
111 Knobil, K., et al., "Adding salmeterol is more effective than increasing the dose of fluticasone for patients with asthma who are symptomatic on low dose fluticasone," European Respiratory Review, Copenhagen, DK, vol. 12, Suppl. 29, Dec. 1998, pp. 19S-20S.
112 Kooreman, et al., "The synthesis of 17-esters of corticosteroids protection of 11beta-hydroxyl of the trimethylsilyl group," Synthetic Communications, vol. 1, No. 2, pp. 81-87, 1971.
113 Kooreman, et al., "The synthesis of 17-esters of corticosteroids protection of 11β-hydroxyl of the trimethylsilyl group," Synthetic Communications, vol. 1, No. 2, pp. 81-87, 1971.
114 Laforce, et al., "Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents," J. Fam. Pract., 1994, vol. 38, No. 2, pp. 145-152.
115 Lane, S. J., et al., "Evaluation of a new capillary electrochromatography/mass spectrometry interface using short columns and high field strengths for rapid and efficient analyses," Rapid Communications in Mass Spectrometry, vol. 10, 1996, pp. 733-736.
116 Lewis, Sarah A., et al., "Association of specific allergen sensitization with socioeconomic factors and allergic disease in a population of Boston women," J. Allergy Clin. Immunol., vol. 107, No. 4, Apr. 2001, pp. 615-622.
117 Li, et al., "Synthesis of aryl 5-(2-chlorophenyl)-2-furoates under phase transfer catalysis," Synthetic Communications, vol. 32, No. 20, pp. 3081-3086, 2002.
118 Linder, "Symptom scores as measurements of the severity of rhinitis," Clinical Allergy, 1988, vol. 18, pp. 29-37.
119 Lumry, William R., "A review of the preclinical and clinical data of newer intranasal steroids in the treatment of allergic rhinitis," Allergy Clin. Immunol., Oct. 1999, 104 (4 Pt 1), pp. S150-S158 plus one correction page.
120 Lutsky, et al., "A novel class of potent topical antiinflammatory agents: 17-benzolyated, 7a-halogeno substituted corticosteroids," Arzneimettelforschung ("Drug Research"), 1978, vol. 29, No. 11, pp. 1662-1667.
121 Lyseng-Williamson, Katherine A., et al., "Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease," Am. J. Respir. Med., vol. 1, No. 4, 2002, pp. 273-282.
122 Mahoney, Janette M., et al., "Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea," Current Eye Research, vol. 4, No. 5, 1985, pp. 531-535.
123 Malhotra Exhibit A, Aug. 2011.
124 Malhotra Exhibit B, Aug. 2011.
125 Maus Exhibit B, Aug. 2011.
126 May, Percy, et al., "May's Chemistry of Synthetic Drugs," Fifth Edition, 1964, pp. 12-17, Longmans.
127 McNeely, Wendy, et al., "Intranasal Azelastine: A Review of its Efficacy in the Management of Allergic Rhinitis," Drugs, 1998, vol. 56, No. 1, pp. 91-114.
128 Mealy, N. E., et al., "Ciclesonide: treatment of allergic rhinitis antiallergy/antiasthmatic," Drugs of the Future, Prous Science, ES, vol. 26, No. 11, Nov. 2001, pp. 1033-1039.
129 Meltzer, Eli O., "Allergic rhinitis: Managing the pediatric spectrum," Allergy and Asthma Proceedings, Jan.-Feb. 2006, vol. 27, No. 1, pp. 2-8, Oceanside Publications, Inc., USA.
130 Meltzer, et al., "Onset of therapeutic effect of fluticasone propionate aqueous nasal spray," Ann. Allergy Asthma Immunol., 2001, vol. 86, No. 3, pp. 286-291.
131 Millard, Jeffrey W., et al., "Solubilization by cosolvents establishing useful constants for the log-linear model," Int'l Journal of Pharmeceutics, vol. 245, 2002, pp. 153-166.
132 Mistry, Nisha, et al., "Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS," Journal of Pharmaceutical and Biomedical Analysis, vol. 16, 1997, pp. 697-705.
133 Mistry, Nisha, et al., "Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements," Journal of Pharmaceutical and Biomedical Analysis, vol. 19, 1999, pp. 511-517.
134 Möllmann, H., et al., Handbook of pharmacokinetic/pharmacodynamic correlation, Chapter 14, Pharmacokinetic-Pharmacodynamic Correlations of Corticosteroids, 323-336, CRC Press, 1995.
135 Moreno-Vargas, et al., "Synthesis and gylcosidase inhibitory activities of 5-(1′,4′-dideoxy-1′,4′-imino-D-erythrosyl)-2-methyl-3-furoic acid (=5-[(3S,4R)-3,4-dihydroxypyrrolidin-2-yl]-2methylfuran-3-carboxylic acid) derivatives: new leads as selective alpha-L-fucosidase and beta-galactosidase inhibitors," Helvetica Chimica Acta, vol. 86, pp. 1894-1913, 2003.
136 Naedele-Risha, R., et al., "Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long acting beta-agonists with inhaled corticosteroids," The Journal of the American Osteopathic Association, vol. 101, No. 9, Sep. 2001, pp. 526-533.
137 Nathan, et al., "A once daily fluticasone proprionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis," Annals of Allergy, 1991, vol. 67, pp. 332-338.
138 Nelson, Harold, S., et al., Fluticasone propionate-salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast, J. Allergy Clin. Immunol., vol. 106, No. 6, Dec. 2000, pp. 1088-1095.
139 Nielsen, et al., "Intranasal corticosteroids for allergic rhinitis: superior relief?" Drugs, 2001, vol. 61, No. 11, pp. 1535-1691.
140 Nielsen, Lars P., "Comparison of Intranasal Corticosteroids and Antihistamines in Allergic Rhinitis, A Review of Randomized, Controlled Trials," Am. J. Respir Med. 2003, vol. 2, No. 1, Cover page, publishing page, pp. 55-65., ADIS International Limited.
141 Nielsen, Lars Peter, et al., "Intranasal Corticosteroids for Allergic Rhinitis, Superior Relief?," Drugs 2001, vol. 61, No. 11, pp. 1563-1579, ADIS International Ltd.
142 Notice of Allowance dated Oct. 3, 2011 (33 pages) in U.S. Appl. No. 10/518,016, filed Jul. 6, 2005.
143 Notice of Non-responsive Amendment dated Jul. 6, 2011 (3 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
144 Notice of Opposition to the grant of patent on Patent Application No. 762/2001 (140397) (Pakistan), 2010.
145 Observations on patentability of the object of the patent application PV 2003-352 (Czech Republic), 2003.
146 O'Conner, B. J., "Combination therapy," Pulmonary Pharmacology and Therapeutics, vol. 11, No. 5/6, 1998, pp. 397-399.
147 Office Action (Final) dated Feb. 18, 2011 (23 pages), U.S. Appl. No. 12/508,388, filed Jul. 23, 2009.
148 Office Action (Final) dated Feb. 24, 2011 (20 pages), U.S. Appl. No. 12/508,393, filed Jul. 23, 2009.
149 Office Action (Final) dated May 3, 2011 (8 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
150 Office Action dated Apr. 28, 2010, (29 pages), U.S. Appl. No. 10/518,016, filed Jul. 6, 2005.
151 Office Action dated Apr. 7, 2011 (3 pages) from counterpart application, AU2009243420.
152 Office Action dated Aug. 31, 2010 (6 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
153 Office Action dated Feb. 16, 2011, (22 pages), U.S. Appl. No. 10/518,016, filed Jul. 6, 2005.
154 Office Action dated Jan. 23, 2009, (27 pages), U.S. Appl. No. 10/518,016, filed Jul. 6, 2005.
155 Office Action dated Jul. 11, 2011-20632 IL.
156 Office Action dated Jul. 11, 2011—20632 IL.
157 Office Action dated Mar. 29, 2011 (3 pages) from counterpart application, AU2009243422.
158 Office Action dated Nov. 30, 2010 (16 pages), U.S. Appl. No. 12/374,523, filed Jan. 21, 2009.
159 Office Action dated Sep. 15, 2011 of U.S. Appl. No. 12/508,393, filed Jul. 23, 2009.
160 Office Action dated Sep. 30, 2010, U.S. Appl. No. 12/508,388, filed Jul. 23, 2009, 22 pages.
161 Office Action dated Sep. 30, 2010, U.S. Appl. No. 12/508,393, filed Jul. 23, 2009, 31 pages.
162 Office Action dated Sep. 9, 2011 of U.S. Appl. No. 12/508,388, filed Jul. 23, 2009.
163 Ong, John T. H., et al., "Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide," Arch Dermatol, vol. 125, Dec. 1989, pp. 1662-1665.
164 Ong, John T. H., et al., "Micellar solubilization of timobesone acetate in aqueous and aqueous propylene glycol solutions of nonionic surfactants," Pharmaceutical Research, vol. 5, No. 11, 1988, pp. 704-708.
165 Onrust, et al., "Mometasone furoate, a review of its intranasal use in allergic rhinitis," Drugs, vol. 56, No. 4, Oct. 1998, pp. 725-745, vol. 21.
166 Opponent's R116 Submission for EP1519731, 2011.
167 Opponent's Statement of Opposition for EP1519731, 2011.
168 Opponent's submission dated Oct. 6, 2011 to EP Patent No. 1519731.
169 Opponent's submission dated Sep. 23, 2011 regarding additional documents on EP Patent No. 1519731.
170 Opponent's submission dated Sep. 23, 2011 regarding list of attendees at oral proceedings on EP Patent No. 1519731.
171 Opposition to EP 1518731, Aug. 8, 2011, 19 pages.
172 Patentee's response of Sep. 6, 2010 of EP Patent No. 1519731.
173 Patentee's submission dated Oct. 5, 2011 to EP Patent No. 1519731.
174 Patentee's submission dated Sep. 19, 2011 on EP Patent No. 1519731.
175 Patentee's submission dated Sep. 29, 2011 regarding list of attendees at oral proceedings on EP Patent No. 1519731.
176 PCT/GB01/03495, International Preliminary Examination Report, date of mailing: Aug. 30, 2002.
177 Pettersson, Bertil, et al., "Re-evaluation of the classical mycoplasma lipophilum cluster (Weisburg, et al., 1989) and description of two new clusters in the hominis group based on 16S rDNA sequences," Int'l Journal of Systematic & Evolutionary Microbiology, 2001, vol. 51, pp. 633-643.
178 Phillips, G. H., et al., "Synthesis and structure activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane—17B-carbothioates and—17B-carboselenoates," Journal of Medicinal Chemistry, 1994, vol. 37, pp. 3717-3729.
179 Popper, T. L., et al., "Structure-activity relationship of a series of novel topical corticosteroids," Journal of Steroid Biochemistry, 1987, vol. 27, pp. 837-843.
180 Portman, D. et al., "Acceptability of local treatment of allergic rhinitis with a combination of a corticoid (beclomethasone) and an antihistaminic (azelastine)", Database Medline, 2000, vol. 121, No. 4, pp. 273-279, XP-002252974.
181 Pre-Grant Opposition, Indian Patent Application 2092/KOLNP/2007 dated Jun. 8, 2007, 183 pages.
182 Prescribing Information for Asteproe, Nov. 2010, 20 pages, Meda Pharmaceuticals Inc., Somerset, NJ, US.
183 Prescribing Information for Rhinocort Aqua™, Dec. 2010, 32 pages, AstraZeneca LP, Wilmington, DE, US.
184 Preservative, definition of, Composite definition of preservative in the medical dictionary from internet site http://medical-dictionary.thefreedictionary.com/preservative(1 of 3), dated Nov. 4, 2009, 3 pages.
185 Product Information Flonase (Fluticasone proprionate) Nasal Spray 50 mcg, 2004, pp. 1-13.
186 Product Information Rhinocort Aqua (budesonide) Nasal Spray 32 mcg, 2005, pp. 1-2.
187 Product Information, Nasonex®, Aug. 2001, 22 pages, Schering Corporation, Kenilworth, NJ, US.
188 Product Specification Bulletin, Avicel® CL-611, Bulletin AVC611-SPEC02/09.RS, 2 pages, FMC BioPolymer, Feb. 2009.
189 Product Specification Bulletin, Avicel® CL-611, Bulletin AVC611-SPEC-02/09.RS, 2 pages, FMC BioPolymer.
190 Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-SPEC-02/09.RS, 2 pages, FMC BioPolymer, Feb. 2009.
191 Product Specification Bulletin, Avicel® RC-591, Bulletin AVC591-SPEC-02/09.RS, 2 pages, FMC BioPolymer.
192 Rapid response report: summary with critical appraisal, fluticasone furoate versus fluticasone propionate for seasonal allergic rhinitis: a review of the clinical and cost-effectiveness, Jun. 13, 2011, Fluticasone Furoate for Seasonal Allergic Rhinitis.
193 Ratner, Paul H., et al., "A Comparison of the Efficacy of Fluticasone Propionate Aqueous Nasal Spray and Loratadine, Alone and in Combination, for the Treatment of Seasonal Allergic Rhinitis," The Journal of Family Practice, Aug. 1998, vol. 47, No. 2, pp. 118-125, Appleton & Lange.
194 Ratner, Paul H., et al., "Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis," Annals of Allergy, Asthma & Immunology, Jan. 2008, vol. 100, Cover page, publishing page, pp. 74-81.
195 Reddy, Indra K., ed., "Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach," 1996, pp. 382-385 plus cover page and publication page, Technomic Publishing Company, Inc.
196 Result of oral proceedings dated Oct. 12, 2011 of EP Patent No. 1519731.
197 Safety Data Sheet, SDS No. 110536, Jun. 23, 2008, V13, Beconase Hayfever Allergy Spray, 5 pages, GlaxoSmithKline.
198 Safety Data Sheet, SDS No. 110556, Jul. 4, 2008, V14, Flonase Nasal Spray, 5 pages, GlaxoSmithKline.
199 Sakagami, et al., "Mucoadhexive BDP microspheres for powder inhalation—their unique pharmacokinetic-pharmacodynamic profiles," Respiratory Drug Delivery, vol. VI, pp. 193-199, 1998.
200 Salib Rami Jean, et al., "Safety and Tolerability Profiles of Intranasal Antihistamines and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis," Drug Safety 2003, vol. 26, No. 12, Cover page, publication page, pp. 863-893, ADIS Data Information BV.
201 Salib, et al.; "Safety and Tolerability Profiles of Intranasal Anihistaminese and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis;" Drug Safety; 2003; vol. 26, No. 12, pp. 829-911.
202 Sandham, et al., "Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate esters," Bioorganic & Medicinal Chemistry, 2004, vol. 12, pp. 5213-5224.
203 Scadding, et al., "Clinical and physiological effects of fluticasone propionate aqueous nasal spray in the treatment of perennial rhinitis," Rhinology, 1991, Suppl. 11, pp. 37-43.
204 Schmidt, M. W., "The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis," Journal of Clinical Pharmacology, 1999, vol. 39, pp. 1062-1069.
205 Search Report dated May 12, 2009 of EP 09075100.
206 Search Report dated May 12, 2009 of EP 09075101.
207 Settipane, et al., "Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study," Clin. Ther., 1995, vol. 17, No. 2, pp. 252-263.
208 Shapiro, et al., "17 heteroaroyl esters of corticosteroids 2. 11 beta hydroxy series," Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 30, No. 9, 1987, pp. 1581-1588.
209 Shapiro, et al., "17-esters and 17,21-diesters of 9-alpha, 11-beta-dichlorocorticoids. Synthesis and anti-inflammatory activity," Steroids, vol. 9, No. 2, pp. 143-156, 1967.
210 Shapiro, et al., "Synthesis and structure-activity studies of corticosteroid 17-heterocyclic aromatic esters. 1. 9-alpha, 11-beta dichloro series," Journal of Medicinal Chemistry, vol. 30, No. 6, pp. 1068-1073, 1987.
211 Shenfield, "Fixed drug combinations: which ones can be recommended?" Current Therapeutics, 1986, pp. 15-29.
212 Simpson, Richard J., "Budesonide and terfenadine, separately and in combination, in the treatment of hay fever," Annals of Allergy, Dec. 1994, vol. 73, Cover page, publication page, pp. 497-502.
213 Smith, et al., "In vitro glucocorticoid receptor binding and transcriptional activiation by topically active glucocorticoids," Arzneimettelforschung, 1998, 48(II)(9), pp. 956-959.
214 Smith, N., et al., "Comparison of the electroosmotic flow profiles and selectivity of stationary phases used in capillary electrochromatography," Journal of Chromatography A., vol. 832, 1999, pp. 41-54.
215 Souness, et al., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors," Immunopharmacology, 2000, vol. 47, Nos. 2/3, pp. 127-162.
216 Spector, Sheldon, "Ideal pharmacotherapy for allergic rhinitis," J Allergy Clin Immunol, 1999, vol. 103, No. 3, Part 2, pp. S386-S387, Mosby, Inc..
217 Spector, Sheldon, "Ideal pharmacotherapy for allergic rhinitis," J Allergy Clin Immunol, vol. 103, No. 3, Part 2, pp. S386-S387, 1999.
218 Stempel, et al., "Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines," Am. J. Man. Care, 1998, vol. 4, pp. 89-96.
219 Study No. 03DMW062—"Pharmacokinetics of GW685698X and CC118781 (fluticasone propionate) when co-administered by the intratracheal or intravenous route to the anaesthetised white pig," 2004.
220 Study No. B30947—"The Pharmacokinetics of GW685698X and CC118781 following intratracheal co-administration to the anaesthetised white pig," 2003.
221 Szefler, Stanley J., et al., Chapter 21, "Glucocorticoids in severe asthma: mechanisms of action and route of administration," Difficult Asthma, pp. 371-375, Martin Dunitz Ltd., Informa Health Care, 1999.
222 Tanaka, et al., "Synthesis of 4H-furo[3,2-b]indole derivatives. III (1). Preparation of 4H-furo[3,2-b]indole-2-carboxylic acid derivatives," Journal Heterocyclic Chemistry, vol. 16, pp. 785-788, 1979.
223 The United States Pharmacopoeia, 23rd Ed., US Pharmacopoeia Convention, Inc., Rockville MD, 1995, pp. 1843-1844, "Physical Tests / (941) X-Ray Diffraction."
224 Togashi, et al., 9-fluoro-11B, 17, 21-trihyrdroxy-16a-methyl-1,4-pregnadiene-3, 20-dione 21-cyclohexanecarboxylate 17-cyclopropanecarboxylate (ST126); Oyo Yakuri, 2002, vol. 63, No. 5/6, pp. 61-77.
225 Ueno, et al., "Synthesis and evaluation of antiinflammatory activities of a series of corticosteroid 17. Alpha-esters containing a functional group," Journal of Medicinal Chemistry, American Chemica Society, vol. 34, No. 8, Aug. 1991, pp. 2468-2473.
226 Undem, et al., "Neural integration and allergic disease," J. Allergy Clin. Immunol., 2000, vol. 106, No. 5, pp. S213-S220.
227 Van AS, et al., "Once daily flluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate," J. Allergy Clin. Immunol., 1993, vol. 91, No. 6, pp. 1146-1154.
228 Van Bavel, et al., "Ocular efficacy and clinician overall evaluation of intranasal fluticasone proprionate (FP) versus loratadine (LOR) in seasonal allergic rhinitis (SAR)," Annals of Allergy, Asthma, & Immunology, 1997, vol. 78, p. 128, Abstract P101.
229 Van Der Molen, et al., "Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids," Thorax, vol. 52, No. 6, 1997, pp. 535-539.
230 Vanrell, "Preservatives in ophthalmic formulations: an overview," Arch. Soc. Esp. Oftalmol., 2007, vol. 82, pp. 531-532.
231 Veramyst (fluticasone furoate) Nasal Spray, GlaxoSmithKline, 2007, Summary Sheet, pp. 1-20.
232 Wang, De-Yun, "Treatment of Allergic Rhinitis: H1-Antihistamines and Intranasal Steroids," Current Drug Targets-Inflammation & Allergy, 2002, vol. I, pp. 215-220, Bentham Science Publishers Ltd.
233 Wang, De-Yun, "Treatment of Allergic Rhinitis: H1-Antihistamines and Intranasal Steroids," Current Drug Targets—Inflammation & Allergy, 2002, vol. I, pp. 215-220, Bentham Science Publishers Ltd.
234 Wenkert, et al., "Short syntheses of furan and catechol derivatives. A synthesis of hydrourushiol1,2," Journal American Chemical Society, vol. 105, pp. 2021-2029, 1983.
235 Westlund, et al., "Fluticasone propionate aqueous nasal spray 200 mg once daily provides relief of ocular symptoms associated with seasonal allergic rhinitis," 57th Annual Meeting of the American Academy of Allergy, Asthma and Immunology, New Orleans LA, Mar. 16-21, 2001, Abstract No. 522.
236 Wiseman, Lynda R., et al., "Intranasal Fluticasone Propionate: A Reappraisal of its Pharmacology and Clinical Efficacy in the Treatment of Rhinitis," Drugs, 1997, vol. 53, No. 5, pp. 885-907, Adis International Limited.
237 Woodford, et al., "Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream," Int'l Journal of Pharmaceutics, 1985, vol. 26, pp. 145-155.
238 World Review 2001: The Pharmaceutical Market, vol. 1 International, IMC Health, 2001, cover, preface, and copyright pages plus pp. 4-42 and 5-1 through 5-11, IMS A.G.
US8859531 Nov 18, 2011 Oct 14, 2014 Hanlim Pharmaceutical Co., Ltd Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration
US20140219949 * Jun 22, 2011 Aug 7, 2014 Jiangsu Deda Pharmaceuticals Co. Ltd Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
International Classification A61P27/14, A61P11/06, A61K31/57, A61K9/00, A61K31/573, A61K31/58, A61P11/00, A61K31/56, A61P37/08, A61K31/55
Cooperative Classification A61K9/10, A61K47/38, A61K47/26, A61K47/186, A61K47/183, A61K47/10, A61K31/58, A61K31/56, A61K9/0043, A61K31/573, A61K31/55
European Classification A61K31/573, A61K31/55, A61K31/58
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LULLA, AMAR;MALHOTRA, GEENA;REEL/FRAME:032610/0399